Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma

Cancer Letters

Volumn 292, Issue 1, 2010, Pages 54-63

  Park, Sung Jin ^a   Kim, Myung Jin ^a   Kim, Yu Kyoung ^a   Kim, Soung Min ^a   Park, Ju Yong ^b   Myoung, Hoon ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Cetuximab; Epidermal growth factor receptor; Genistein; Oral squamous cell carcinoma

Indexed keywords

CD31 ANTIGEN; CETUXIMAB; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; MOUTH TUMOR; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GENISTEIN; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951239433     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.004     Document Type: Article

References (31)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics 2002. CA Cancer J. Clin. 2005, 55:74-108.
2. Kim E.S., Kies M., Herbst R.S. Novel therapeutics for head and neck cancer. Curr. Opin. Oncol. 2002, 14(3):334-342.
3. Lingen M.W., Emami B., Clark J.I. New therapeutic strategies for the treatment and prevention of head and neck cancer. Expert Opin. Invest. Drugs 2000, 9(12):2855-2872.
4. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 1987, 56881-56914.
5. Wells A. EGF receptor. Int. J. Biochem. Cell Biol. 1999, 31(6):637-643.
6. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37(Suppl. 4):4S3-8.
7. Moscatello D.K., Holgado-Madruga M., Emlet D.R., Montgomery R.B., Wong A.J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 1998, 273(1):200-206.
8. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995, 55(14):3140-3148.
9. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 2002, 29(1 Suppl. 4):27-36.
10. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 2002, 20(18 Suppl.):1S-13S.
11. Sridhar S.S., Seymour L., Shepherd F.A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003, 4(7):397-406.
12. Akiyama T., Ogawara H. Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Methods Enzymol. 1991, 201362-201370.
13. Ravindranath M.H., Muthugounder S., Presser N., Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol. 2004, 546121-546165.
14. Dorai T., Aggarwal B.B. Role of chemopreventive agents in cancer therapy. Cancer Lett. 2004, 215(2):129-140.
15. Myoung H., Hong S.P., Yun P.Y., Lee J.H., Kim M.J. Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci. 2003, 94(2):215-220.
16. Bosari S. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum. Pathol. 1992, 23:755-761.
17. Fotsis T., Pepper M.S., Montesano R., Aktas E., Breit S., Schweigerer L., et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin. Endocrinol. Metab. 1998, 12(4):649-666.
18. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350(21):2129-2139.
19. Gleich L.L., Zimmerman N., Wang Y.O., Gluckman J.L. Angiogenic inhibition for the treatment of head and neck cancer. Anticancer Res. 1998, 18:2607-2609.
20. Mendelsohn J. Jeremiah Metzger lecture, targeted cancer therapy. Trans. Am. Clin. Climatol. Assoc. 2000, 111:95-110.
21. Bruns C.J., Harbison M.T., Davis D.W., Portera C.A., Tsan R., McConkey D.J., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000, 6(5):1936-1948.
22. Inoue K., Slaton J.W., Perrotte P., Davis D.W., Bruns C.J., Hicklin D.J., et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 2000, 6(12):4874-4884.
23. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59(8):1935-1940.
24. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004, 64(15):5355-5362.
25. Matar P., Rojo F., Cassia R., Moreno-Bueno G., Di Cosimo S., Tabernero J., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 2004, 10(19):6487-6501.
26. Janmaat M.L., Kruyt F.A., Rodriguez J.A., Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 2003, 9(6):2316-2326.
27. Li B., Chang C.M., Yuan M., McKenna W.G., Shu H.K. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. 2003, 63(21):7443-7450.
28. Rianco B., Shin I., Ritter C.A., Yakes F.M., Basso A., Rosen N., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22(18):2812-2822.
29. Dhe S.Q., Solit D., Basso A., Moasser M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin. Cancer Res. 2003, 9(12):4340-4346.
30. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J. Clin. Oncol. 2001, 19(18 Suppl.):41S-44S.
31. Gadgeel S.M., Ali S., Philip P.A., Wozniak A., Sarkar F.H. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 2009, 115(10):2165-2176.